Hyphens Pharma International Ltd. · SGX:1J5
Hyphens Pharma International — Investor Presentation (May 2022)
17 slides from Hyphens Pharma International's investor presentation, May 27, 2022
Slide 1: SGX General Announcement: Corporate Presentation - DocMed
5/27/22, 12:32 PM General Announcement::CORPORATE PRESENTATION - DOCMED GENERAL ANNOUNCEMENT::CORPORATE PRESENTATION - DOCMED Issuer & Securities Issuer/ Manager HYPHENS PHARMA INTERNATIONAL LIMITED Securities HYPHENS PHARMA INTL LIMITED - SG1EE4000006 - 1J5 Stapled Security No Announcement Details
Slide 2: DocMed Received S$6M Investment to Grow Digital Healthtech
HYPHENS PHARMA INTERNATIONAL LIMITED DOCMED RECEIVED S$6M INVESTMENT TO GROW DIGITAL HEALTHTECH 27 MAY 2022
Slide 3: Disclaimer
DISCLAIMER This presentation has been prepared by Hyphens Pharma International Limited (the "Company" and, together with its subsidiaries, the "Group"). This content in this presentation is being furnished to you on a confidential basis and solely for your information and neither this presentation n
Slide 4: About DocMed Technology
ABOUT DOCMED TECHNOLOGY DocMed Technology, a wholly owned subsidiary of Hyphens Pharma International, was incorporated in Oct 2021 for the purpose of investment holding and development of an integrated digital healthtech platform with various healthtech solutions, to cater to various healthcare stak
Slide 5: Our Core Mission
OUR CORE MISSION We are the platform that empowers doctors and healthcare stakeholders through technology and network effect to meet patient needs and optimise health outcome
Slide 6: Digital Assets Overview
DIGITAL ASSETS OVERVIEW DocCentral + + 2001 Year of establishment 120+ Doctors + Telehealth Providers at launch phase 6 Key digital tools for doctors’ disposal 500k+ Visitor logins per annum ~80 Average daily 80 Doctors for trial testing e-prescriptions during during MVP phase Number of transactions
Slide 7: Leadership
LEADERSHIP Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group
Slide 8: Timothy Chen, CEO
TIMOTHY CHEN • Has been appointed CEO designate since the inception of DocMed Technology. • A well-balanced investment management, corporate management and entrepreneurial start up experiences over the past 18 years in the various industries of investment banking, private equity/venture capital inve
Slide 9: Details of Series A Fund Raised
DETAILS OF SERIES A FUND RAISED
Slide 10: Details of Transaction
DETAILS OF TRANSACTION • Lead Investor – Metro ARC Investment Pte Ltd, a wholly owned subsidiary of Metro Holdings Ltd. • Investment into DocMed Technology • Fund Raised – S$6 million for a 10% • Instrument – Preference Share • Post Money Valuation of DocMed Technology – S$60m
Slide 11: Rationale of Transaction
RATIONALE OF TRANSACTION aii n 7s Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group g Hyphens
Slide 12: Rationale of Transaction
RATIONALE OF TRANSACTION • To consolidate all digital assets of the Hyphens Group under DocMed to develop an integrated digital healthtech platform, including existing assets of POM (Singapore’s leading B2B digital hypermart) and WellAway Pharmacy, both of which are operated by Pan-Malayan Pharmaceu
Slide 13: Usage of Funds $6M
USAGE OF FUNDS BREAKDOWN IN $MIL To develop an integrated healthtech platform Team 30% Recruitment of manpower talent in digital and Expansion operational expertise across the region 50% $6M Expansion of existing key digital assets in countries, such as Malaysia, Vietnam and other ASEAN countries Pr
Slide 14: Post Deal Restructuring
POST DEAL RESTRUCTURING Singapore's Leading Specialty Pharmaceutical and Consumer Healthcare Group
Slide 15: Post Deal Completion Structure
POST DEAL COMPLETION STRUCTURE 89.76% POM Medical HPIL Hypermart (Digital Asset) 10.00% 100% Pan-Malayan METRO DocMed Tech Pharmaceuticals 0.24% WellAway Timothy Chen Pharmacy (Digital Asset)
Slide 16: Financial Effects
FINANCIAL EFFECTS Pre-Deal Post-Deal (1) NTA of the Group as at 31 December 2021 (S$’000) 34,483 39,713 Number of issued shares in the share capital of the 308,776 308,776 Company (‘000) NTA per share (S$ cents) 11.17 12.86 FY2021 profit attributable to the shareholders of the 6,846 6,793 Company (S
Slide 17: Hyphens Pharma International Limited contact details
Hyphens Pharma International Limited (SGX: 1J5) 16 Tai Seng Street, Level 4, Singapore 534138 www.hyphensgroup.com
Hyphens Pharma International — Investor Presentation (May 2022) on 6ix